White Pine Capital’s Harvard Bioscience HBIO Stock Holding History

White Pine Capital’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,270	Closed	-$28K	–	216
2020 Q1	$28K	Sell	1,270 -280	-18%	-$7.59K	0.01%	202
2019 Q4	$47K	Hold	1,550	–	–	0.02%	217
2019 Q3	$48K	Hold	1,550	–	–	0.02%	226
2019 Q2	$31K	Hold	1,550	–	–	0.01%	225
2019 Q1	$67K	Hold	1,550	–	–	0.02%	218
2018 Q4	$49K	Sell	1,550 -260	-14%	-$10.2K	0.02%	209
2018 Q3	$95K	Hold	1,810	–	–	0.03%	222
2018 Q2	$97K	Sell	1,810 -1,010	-36%	-$51.7K	0.03%	228
2018 Q1	$141K	Hold	2,820	–	–	0.05%	226
2017 Q4	$93K	Hold	2,820	–	–	0.03%	212
2017 Q3	$106	Hold	2,820	–	–	﹤0.01%	212
2017 Q2	$72K	Hold	2,820	–	–	0.03%	214
2017 Q1	$73K	Buy	+2,820	New	+$81.2K	0.03%	206

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

White Pine Capital's HBIO Position: Q2 2020 in Review

White Pine Capital sold out of Harvard Bioscience (HBIO) in Q2 2020, closing a stake of 1,270 shares — an estimated $28K sold.

White Pine Capital first reported a position in HBIO in Q1 2017 and held it in 13 quarters. The position peaked at $141K in Q1 2018. 87 funds tracked by Wall St. Rank hold HBIO as of Q2 2020.

White Pine Capital reported no remaining Harvard Bioscience position as of Q2 2020 after selling out during the quarter.
White Pine Capital sold 1,270 Harvard Bioscience shares in Q2 2020, an estimated $28K.
White Pine Capital first reported a position in Harvard Bioscience in Q1 2017 and held it in 13 quarters.
White Pine Capital's Harvard Bioscience position peaked at $141K in Q1 2018.
87 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2020.

Based on White Pine Capital's 13F filing for Q2 2020, filed 12 Aug 2020.